x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Cannabinoid and Psychedelic Pharmacology and Drug Development

Jim Mitchell and Google NotebookLM

Explore Cannabinoid and Psychedelic Pharmacology with AI-Powered Learning.Welcome to a groundbreaking approach to mastering cannabinoid and psychedelic pharmacology and the FDA drug development pathway! This podcast series, powered by Google’s Notebook LM, offers a cutting-edge, AI-guided learning experience tailored for formal classes or self-directed study.Each 30-day series delves deep into the science of cannabinoid and psychedelic pharmacology, exploring molecular signaling pathways,

science chemistry

All Episodes

20:37

30 Day FDA Drug Development in Cannabinoid and...

Cannabinoid and Psychedelic Pharmacology and Drug... ·

2025/01/31

This podcast episode explores the application of Six Sigma and continuous improvement tools in natural product manufacturing, particularly focusing on cannabis and psychedelic compounds. The discussion covers:- The DMAIC (Define, Measure, Analyze, Improve, Control) methodology and its practical applications- Quality by Design (QbD) principles and risk management frameworks- Real-world case studies, including improving terpene profile consistency in cannabis extracts and controlling impurities in

en

46:36

30 Day FDA Drug Development in Cannabinoid and...

Cannabinoid and Psychedelic Pharmacology and Drug... ·

2025/01/31

This podcast episode explores the complex challenges of scaling up production of cannabinoid and psychedelic APIs (Active Pharmaceutical Ingredients) from laboratory to commercial scale. Using Watson's Pharmaceutical Process Development as a guide, the discussion covers key aspects including:- Balancing yield maximization, cost minimization, and waste management while maintaining product safety and efficacy- The differences between batch and continuous processing methods- Specific challenges with

en

10:22

30 Day FDA Drug Development in Cannabinoid and...

Cannabinoid and Psychedelic Pharmacology and Drug... ·

2025/01/31

This podcast episode explores global regulations for cannabis and psychedelic therapies, comparing approaches between the US FDA, Canada, and the EU. The discussion covers ICH guidelines for harmonizing drug development standards internationally, the role of botanical drug classifications, and the challenges of balancing innovation with accessibility. Key topics include mutagenic impurity guidelines, analytical procedures for quality control, and the integration of real-world data with clinical

en

18:04

30 Day FDA Drug Development in Cannabinoid and...

Cannabinoid and Psychedelic Pharmacology and Drug... ·

2025/01/31

This podcast episode explores intellectual property rights in cannabinoid and psychedelic drug development. The discussion covers various aspects of patent protection, including novel drug formulations, extraction processes, and synthetic analogs. The speakers examine the tension between protecting pharmaceutical innovations and ensuring treatment accessibility, while also addressing the ethical considerations of patenting naturally-derived compounds. The episode delves into topics like orphan drug

en

23:12

30 Day FDA Drug Development in Cannabinoid and...

Cannabinoid and Psychedelic Pharmacology and Drug... ·

2025/01/31

This podcast episode explores pharmacovigilance and post-market surveillance in cannabinoid and psychedelic therapies. The discussion covers how the FDA monitors drug safety after approval, the importance of real-world data collection, and the role of Risk Evaluation and Mitigation Strategies (REMS) in ensuring patient safety. The speakers examine unique challenges in monitoring these therapies, including drug interactions, subjective effects, and the importance of set and setting. They also discuss

en

21:44

30 Day FDA Drug Development in Cannabinoid and...

Cannabinoid and Psychedelic Pharmacology and Drug... ·

2025/01/31

This podcast episode explores the complexities and challenges of clinical trials for cannabinoid therapies. The discussion covers key aspects including:- Dosing variability and product consistency challenges in plant-derived compounds- Patient compliance and addressing stigma around cannabis research- Placebo control difficulties unique to cannabinoid studies- Special considerations for vulnerable populations like children and pregnant womenThe episode also examines promising therapeutic

en

14:47

30 Day FDA Drug Development in Cannabinoid and...

Cannabinoid and Psychedelic Pharmacology and Drug... ·

2025/01/31

This podcast episode explores the complex challenges of designing clinical trials for psychedelic therapies, particularly focusing on unique issues like the placebo effect and functional unblinding. The discussion covers how researchers use active placebos and creative trial designs to control for expectation bias. It also examines the FDA's stance on regulating psychedelic therapy, highlighting the complex relationship between drug approval and therapeutic context. The episode emphasizes the

en

21:56

30 Day FDA Drug Development in Cannabinoid and...

Cannabinoid and Psychedelic Pharmacology and Drug... ·

2025/01/31

This podcast episode explores the societal safety implications of cannabinoids and psychedelics, covering key topics like addiction potential, psychological risks, and substance misuse. The discussion examines how regulatory frameworks and quality control measures like cGMP compliance can help ensure public safety. The episode also delves into the FDA's role in drug approval, the importance of accurate labeling, and the broader ethical considerations of integrating these substances into mainstream

en

13:28

30 Day FDA Drug Development in Cannabinoid and...

Cannabinoid and Psychedelic Pharmacology and Drug... ·

2025/01/31

This episode explores pharmaceutical product lifecycle management, focusing on what happens after FDA drug approval. It explains how companies can make post-approval changes through different regulatory pathways (CBE0, CBE30, and PAS). The discussion covers Quality by Design (QbD) principles, mutagenic impurities, and the unique challenges of botanical drug development. The episode emphasizes the importance of regulatory frameworks in maintaining drug safety and efficacy while allowing for necessary

en

18:31

30 Day FDA Drug Development in Cannabinoid and...

Cannabinoid and Psychedelic Pharmacology and Drug... ·

2025/01/31

This podcast episode explores Process Analytical Technology (PAT) and its transformative impact on manufacturing natural products, particularly cannabinoids and psychedelics. The discussion covers key analytical tools like NIR and Raman spectroscopy, explaining how they enable real-time quality control and monitoring during production. The episode highlights PAT's benefits including reduced waste, improved efficiency, and better regulatory compliance. It also addresses important considerations about

en

17:28

30 Day FDA Drug Development in Cannabinoid and...

Cannabinoid and Psychedelic Pharmacology and Drug... ·

2025/01/31

This podcast episode explores Critical Material Attributes (CMAs) in botanical drug manufacturing, focusing on cannabis and psychedelics. The discussion covers key aspects including:- The unique challenges of working with botanical materials compared to synthetic drugs- Important CMAs like moisture content, particle size, and microbial load that affect product quality- How cultivar selection impacts chemical profiles and final product characteristicsThe episode emphasizes how consistent CMAs are

en

29:34

30 Day FDA Drug Development in Cannabinoid and...

Cannabinoid and Psychedelic Pharmacology and Drug... ·

2025/01/31

This podcast episode explores the critical importance of label accuracy in psilocybin products, drawing parallels to early challenges in the cannabis industry. The discussion covers key topics including:- The use of advanced testing methods like LCMS (liquid chromatography mass spectrometry) to accurately measure psilocybin and psilocin levels- Current challenges in the unregulated market, described as a "Wild West" environment with varying product quality and potency- The FDA's emerging role in

en

10:42

30 Day FDA Drug Development in Cannabinoid and...

Cannabinoid and Psychedelic Pharmacology and Drug... ·

2025/01/31

This episode explores label accuracy in cannabinoid products, with a focus on the challenges and importance of proper labeling in the CBD/THC industry. The discussion covers research from JAMA showing widespread mislabeling issues, the potential dangers of inaccurate labels for consumers, and the critical role of third-party testing and cGMP compliance in ensuring product safety. The conversation also delves into lesser-known cannabinoids like CBG, CBN, and THCV, examining their unique properties

en

16:33

30 Day FDA Drug Development in Cannabinoid and...

Cannabinoid and Psychedelic Pharmacology and Drug... ·

2025/01/31

This episode explores the complexities of botanical drug development, focusing on cannabis and psychedelic mushrooms. The discussion covers key quality control challenges, including the variability of active compounds in natural products and the importance of standardization. The episode explains crucial regulatory frameworks like the Botanical Drug Master File (BDMF) and ICHM7 guidelines, which ensure product safety and consistency. It also delves into extraction methods, purification processes,

en

22:10

30 Day FDA Drug Development in Cannabinoid and...

Cannabinoid and Psychedelic Pharmacology and Drug... ·

2025/01/31

This podcast episode explores the fundamentals of Current Good Manufacturing Practices (cGMP) in pharmaceutical production, with a special focus on emerging cannabinoid and psychedelic therapies. The discussion covers key aspects of cGMP including documentation, quality control, facility standards, and personnel training. The episode delves into historical examples like the thalidomide tragedy to illustrate why strict manufacturing standards are crucial. It also addresses current challenges in

en

30:19

30 Day FDA Drug Development in Cannabinoid and...

Cannabinoid and Psychedelic Pharmacology and Drug... ·

2025/01/31

This podcast episode explores the critical differences between validation and verification in analytical methods, particularly for botanical and fungal products. The discussion covers how validation requirements evolve through different phases of product development, from initial testing to commercial production. Key topics include dealing with natural variability in botanical materials, the importance of robust analytical methods, and how these principles apply to both traditional products and

en

33:42

30 Day FDA Drug Development in Cannabinoid and...

Cannabinoid and Psychedelic Pharmacology and Drug... ·

2025/01/31

This podcast episode explores the critical role of impurity assessments in psychedelic drug development, focusing on two major types: nitrosamine and genotoxic impurities. The discussion covers why these impurities are concerning, with nitrosamines being carcinogenic and genotoxic impurities capable of damaging DNA. The episode delves into detection methods, control strategies, and regulatory requirements, particularly highlighting the challenges specific to psychedelic therapeutics due to their

en

18:31

30 Day FDA Drug Development in Cannabinoid and...

Cannabinoid and Psychedelic Pharmacology and Drug... ·

2025/01/31

This podcast episode explores the fascinating differences between natural botanical extracts and their synthetic counterparts, with a focus on impurities. It delves into how the endocannabinoid system (ECS) interacts with these compounds and introduces the concept of polypharmacy - where multiple compounds work together synergistically. The discussion covers important aspects like variability in natural products, standardization challenges, and safety considerations, while highlighting how these

en

25:10

30 Day FDA Drug Development in Cannabinoid and...

Cannabinoid and Psychedelic Pharmacology and Drug... ·

2025/01/31

This deep-dive podcast episode explores the critical world of drug impurities and their impact on pharmaceutical safety. The discussion covers the ICH guidelines (Q3A through Q3E) that govern impurity control, sophisticated analytical techniques for detection, and real-world applications in both traditional pharmaceuticals and emerging substances like cannabis and psilocybin. The episode breaks down complex concepts like purge factors, nitrosamine impurities, and hyphenated analytical techniques,

en

23:57

30 Day FDA Drug Development in Cannabinoid and...

Cannabinoid and Psychedelic Pharmacology and Drug... ·

2025/01/31

This podcast episode explores the science of stability testing and shelf-life determination for sensitive compounds derived from plants and fungi. The discussion covers two main testing approaches - real-time and accelerated testing- and delves into the complexities of working with multiple active compounds like cannabinoids and fungal metabolites.The episode emphasizes the critical importance of accurate stability testing for consumer safety and product labeling, discussing how compounds can

en

252 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter